Climb Bio, Inc.
CLYM- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001768446
In the last 90 days, Climb Bio, Inc. insiders filed 0 open-market purchases and 1 sale; 108 institutions reported holding it in 13F filings for Q2 2026, worth $734.3M in total; no superinvestor holds it.
Q4 2023 vs. Q3 2023
How the institutions holding Climb Bio, Inc. changed between Q3 2023 and Q4 2023.
All holders in Q4 2023All holders in Q3 2023
| Measure | Q3 2023 | Q4 2023 | Change |
|---|---|---|---|
| Holders | 23 | 23 | 0 |
| Shares | 16.7M | 16.9M | +125.1K (+0.7%) |
| Value | $44.0M | $45.5M | +$1.51M (+3.4%) |
New holders (3)
Institutions that held Climb Bio, Inc. at the end of Q4 2023 but not at the end of Q3 2023.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Cerity Partners LLC | 13,821 | $37.3K | 0.00% |
| Renaissance Technologies LLC | 10,603 | $29.0K | 0.00% |
| JPMorgan Chase & Co | 1 | $3 | 0.00% |
Sold out (3)
Institutions that held Climb Bio, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.
| Institution | Shares, Q3 2023 | Value, Q3 2023 |
|---|---|---|
| Silverarc Capital Management, LLC | 121,110 | $318.5K |
| Stifel Financial Corp | 14,650 | $38.5K |
| UBS Group AG | 89 | $234 |